Tetravalent antibody-scTRAIL fusion proteins with improved properties

Molecular Cancer Therapeutics

Volumn 13, Issue 1, 2013, Pages 101-111

  Seifert, Oliver ^a   Plappert, Aline ^a,b   Fellermeier, Sina ^a   Siegemund, Martin ^a   Pfizenmaier, Klaus ^a   Kontermann, Roland E ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CETUXIMAB; DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E HEAVY CHAIN DOMAIN 2 SINGLE CHAIN TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND FUSION PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE IMMUNOGLOBULIN E HEAVY CHAIN DOMAIN 2 SINGLE CHAIN TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND FUSION PROTEIN; SINGLE CHAIN TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

ADD ON THERAPY; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; DIMERIZATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG HALF LIFE; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SKIN TUMOR; TARGET CELL DESTRUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; CELL LINE, TUMOR; HUMANS; IMMUNOGLOBULIN E; MICE; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892607590     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0396     Document Type: Article

References (43)

1. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8: 782-98.
2. Yang A, Wilson NS, Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr Opin Cell Biol 2010;22:837-44.
3. Mellier G, Huang S, Shenoy K, Pervaiz S. TRAILing death in cancer. Mol Aspects Med 2010;31:93-112.
4. den Hollander MW, Gietema JA, de Jong S, Walenkamp AM, Reyners AK, Oldenhuis CN, et al. Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett 2013;332:194-201.
5. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010;28:2839-46.
6. Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 2010;28:1527-33.
7. Soria JC, Mark Z, Zatloukal P, Szima B, Albert I, Juhasz E, et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 2011;29:4442-51.
8. Gerspach J, Schneider B, Müller N, Otz T, Wajant H, Pfizenmaier K. Generic engineering of death ligands of improved therapeutic activity. Adv Exp Med Biol 2011;691:507-19.
9. Kontermann RE. Antibody-cytokine fusion proteins. Arch Biochem Biophys 2012;526:194-205.
10. Schneider B, Münkel S, Krippner-Heidenreich A, Grunwald I, Wels WS, Wajant H, et al. Potent antitumor activity of TRAIL through generation of tumor-targetedsingle-chain fusionproteins. Cell Death Dis 2010;26:e68.
11. Siegemund M, Pollak N, Seifert O, Wahl K, Hanak K, Vogel A, et al. Superior antitumor activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. Cell Death Dis 2012;3:e295.
12. Berg D, Lehne M, Müller N, Münkel S, Sebald W, Pfizenmaier K, et al. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Diff 2007;14:2021-34.
13. Wajant H, Gerspach J, Pfizenmaier K. Engineering death receptor ligands for cancer therapy. Cancer Lett 2013;332:163-74.
14. H2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity. Protein Eng Des Sel 2012;25:603-12.
15. Wan T, Beavil RL, Fabiane SM, Baevil AJ, Sohi MK, Keown M, et al. The crystal structure of IgE Fc reveals an asymmetrically bent conformation. Nat Immunol 2002;3:681-6.
16. Dorrington KJ, Bennich HH. Structure-function relationships in human immunoglobulin E. Immunol Rev 1978;41:3-25.
17. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1: 1311-8.
18. Müller D, Karle A, Meissburger B, Höfig I, Stork R, Kontermann RE. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007;282: 12650-60.
19. Zettlitz KA, Lorenz V, Landauer K, Münkel S, Herrmann A, Scheurich P, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs 2010;2:639-47.
20. Cuesta AM, Sainz-Pastor N, Bonet J, Oliva B, Álvarez-Vallina L. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol 2010;28:355-62.
21. Sayers TJ, Murphy WJ. Combining protease inhibition with TNFrelated apoptosis-inducing ligand (ApoL2/TRAIL) for cancer therapy. Cancer Immunol Immunother 2006;55:76-84.
22. Kelley SK, Haris LA, Xie D, Deforge L, Totpal K, Bussiere J, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001;299:31-8.
23. Xiang H, Nguyen CB, Kelley SK, Dybdal N, Escandón E. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma colo205 tumor-bearing nude mice. Drug Metab Dispos 2004;32:1230-8.
24. Pan Y, Xu R, Peach M, Huang CP, Branstetter D, Novotny W, et al. Evaluation of pharmacodynamic biomarkers in a phase Ia trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. Br J Cancer 2011;105:1830-8.
25. Wild R, Fager K, Flefleh C, Kan D, Inigo IC, Astaneda S, et al. Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol Cancer Ther 2006;5:104-13.
26. Bremer E, Samplonius DF, van Genne L, Dijkstra MH, Kroesen BJ, de Leij LF, et al. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 2005;280:10025-33.
27. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first protease inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011;11:239-53.
28. Painuly U, Kumar S. Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. Clin Med Insights Oncol 2013;7: 53-73.
29. de Wilt LHAM, Kroon J, Jansen G, de Jong S, Peters GJ, Kruyt FAE. Bortezomib and TRAIL: a perfect match for apoptotic eliminiation of tumour cells? Crit Rev Oncol Hematol 2013;85:363-72.
30. Bevis KS, Buchsbaum DJ, Straughn JM Jr. Overcoming TRAIL resistance in ovarian carcinoma. Gynecol Oncol 2010;119:157-63.
31. Lecis D, Drago C, Manzoni L, Seneci P, Scolastico C, Mastrangelo E, et al. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and bortezomib. Br J Cancer 2010;102:1707-16.
32. Wu XX, Ogawa O, Kakehi Y. TRAIL and chemotherapeutic drugs in cancer therapy. Vitam Horm 2004;67:365-83.
33. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factorrelated apoptosis-inducing ligand/Apol-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 2003;63:5390-400.
34. Baritaki S, Huerta-Yepes Sakai T, Spandidos DA, Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 2007;6:1387-99.
35. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011;22:868-76.
36. Stork R, Müller D, Kontermann RE. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Prot Eng Des Sel 2007;20: 569-76.
37. Stork R, Campigna E, Robert B, Müller D, Kontermann RE. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem 2009;284:25612-9.
38. Hutt M, Fäarber-Schwarz A, Unverdorben F, Richter F, Kontermann RE. Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains. J Biol Chem 2012;287:4462-9.
39. Kontermann RE. Dual targeting strategies with bispecific antibodies. MAbs 2012;4:182-97.
40. Kontermann RE. Alternative antibody formats. Curr Opin Mol Ther 2010;12:176-83.
41. Löfblom J, Frejd FY, Stahl S. Non-immunoglobulin based protein scaffolds. Curr Opin Biotechnol 2011;022:1-6.
42. Shadidi M, Sioud M. Selective targeting of cancer cells using synthetic peptides. Drug Resist Updat 2003;6:363-71.
43. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. 5th ed. NIH Publication no. 91-3242;1991.